Design and synthesis of α-carboxy nucleoside phosphonate analogues and evaluation as HIV-1 reverse transcriptase-targeting agents.

J Org Chem

Department of Chemistry, Analytical and Biological Chemistry Research Facility, Synthesis and Solid State Pharmaceutical Centre, University College, Cork, Ireland.

Published: March 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The synthesis of the first series of a new class of nucleoside phosphonate analogues is described. Addition of a carboxyl group at the α position of carbocyclic nucleoside phosphonate analogues leads to a novel class of potent HIV reverse transcriptase (RT) inhibitors, α-carboxy nucleoside phosphonates (α-CNPs). Key steps in the synthesis of the compounds are Rh-catalyzed O-H insertion and Pd-catalyzed allylation reactions. In cell-free assays, the final products are markedly inhibitory against HIV RT and do not require phosphorylation to exhibit anti-RT activity, which indicates that the α-carboxyphosphonate function is efficiently recognized by HIV RT as a triphosphate entity, an unprecedented property of nucleoside monophosph(on)ates.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jo502549yDOI Listing

Publication Analysis

Top Keywords

nucleoside phosphonate
12
phosphonate analogues
12
α-carboxy nucleoside
8
nucleoside
5
design synthesis
4
synthesis α-carboxy
4
analogues evaluation
4
evaluation hiv-1
4
hiv-1 reverse
4
reverse transcriptase-targeting
4

Similar Publications

Objectives: This study aimed to evaluate the effectiveness of bictegravir (BIC)-based antiretroviral therapy (ART) against HIV-1 sub-subtype A6 viruses carrying the L74I polymorphic mutation in integrase.

Methods: A total of 100 ART-naive people living with HIV from the Moscow Regional AIDS Center were enrolled between May and July 2023. HIV-1 subtypes and baseline drug resistance mutations were analysed prior to treatment initiation.

View Article and Find Full Text PDF

Background: Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.

Methods: In this open-label non-inferiority trial conducted in Port-au-Prince, Haiti, adults (aged 18 years or older) with viral suppression (HIV-1 RNA <200 copies per mL) on second-line regimens including ritonavir-boosted protease inhibitors and two NRTIs were randomised (1:1) using a computer-generated random-number list.

View Article and Find Full Text PDF

We investigated factors associated with HBV-rebound in people with HIV (PWH) with chronic HBV (CHBV) under HBV-active antiretroviral therapy (ART): emtricitabine (FTC)+tenofovir alafenamide (TAF) or 3TC/FTC+ tenofovir disoproxil fumarate (TDF) regimen. The present study included PWH/CHBV followed as outpatients from October 2008 to August 2023 at San Raffaele Hospital, Milan, Italy. The baseline evaluation was the date of first negative HBV-DNA (< 10 IU/mL) after the first positive result before HBV active ART.

View Article and Find Full Text PDF

Introduction: Older adults with HIV, particularly those ≥ 50 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) ≥ 50 years of age across treatment-naïve and virologically suppressed cohorts over a long-term follow-up.

Methods: This post hoc analysis included participants ≥ 50 and < 50 years of age from six phase 3 trials of B/F/TAF, comprising 2 treatment-naïve studies and 4 virologically suppressed studies.

View Article and Find Full Text PDF

Synthesis of -Modified Chimeric Oligonucleotides via Chemoselective Condensation of Nucleoside 3'--Phosphonothioate.

J Org Chem

September 2025

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Katsushika-ku, Tokyo 125-8585, Japan.

Nucleoside 3'--phosphonothioate monoesters possess two nucleophilic atoms, i.e., oxygen and sulfur atoms; therefore, their chemoselectivity must be controlled during condensation with a 5'-hydroxy group for the synthesis of oligonucleotides.

View Article and Find Full Text PDF